|
For further inquiries and interview requests please contact Lightlake Therapeutics Inc:
Dr. Roger Crystal
Chief Executive Officer
+44(0)203 617 8739
For investor information please contact:
Porter, LeVay & Rose, Inc.
Michael J. Porter
mike@plrinvest.com
212-564-4700 |
 |
MEDIA KIT
Welcome to Lightlake Therapeutic Inc. Online Media Kit delivering results of our Placebo-controlled Phase II clinical trial comparing opioid antagonist naloxone and placebo in the treatment of BED, conducted in Helsinki Finland between August 2011 and March 2012.
Please explore the Online Media Kit for the press release containing trial results, background material on binge eating disorder (BED) as well as anonymous participant stories on experiencing Binge Eating Disorder.
About BED
About naloxone
PHOTOS
   
All of the media photos are free for further publishing.
Press images
VIDEOS
|
|
EXPERIENCING BED
Trial participants share their personal stories on experiencing binge eating disorder BED.
|
